Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy by unknown
Wells et al. Thrombosis Journal 2014, 12:26
http://www.thrombosisjournal.com/content/12/1/26ORIGINAL CLINICAL INVESTIGATION Open AccessInfluence of statin use on the incidence of
recurrent venous thromboembolism and major
bleeding in patients receiving rivaroxaban or
standard anticoagulant therapy
Philip S Wells1*, Martin Gebel2, Martin H Prins3, Bruce L Davidson4 and Anthonie WA Lensing2Abstract
Background: Statins may reduce the risk of first and recurrent venous thromboembolism (VTE). No data are
available on their potential benefit in patients treated with the oral anticoagulant rivaroxaban.
Methods: The EINSTEIN DVT/PE and EINSTEIN Extension studies compared rivaroxaban with standard of care (n=8280)
and placebo (n=1188), respectively. The incidences of recurrent VTE and major bleeding per 100 patient-years for
exposure (or not) to statins were calculated. A Cox proportional hazards model was constructed, stratified by index
event and intended treatment duration, with statin use as a time-dependent variable, for each treatment group
(rivaroxaban vs enoxaparin/vitamin K antagonist or placebo) and adjusted for relevant variables.
Results: In EINSTEIN DVT/PE, 1509 (18.3%) patients used statins during the at-risk period, and 6731 (81.7%) did not.
Overall, 2.6 recurrent VTEs occurred per 100 patient-years with statin use compared with 3.8 per 100 patient-years
without statins (adjusted hazard ratio [HR] 0.76; 95% confidence interval [CI] 0.46–1.25). HRs for recurrent VTE were
similar for concomitant use of rivaroxaban-statin and enoxaparin/VKA-statin. Major bleeding events occurred in
3.0 per 100 patient-years with statin use compared with 2.3 per 100 patient-years without statins (adjusted HR
0.77; 95% CI 0.46–1.29). Due to adjustments in the Cox regression model, the direction of this HR is in contrast to
the crude comparison. In EINSTEIN Extension, no recurrent VTEs occurred with statin use in the rivaroxaban group
compared with 1.6 per 100 patient-years without statins. In the placebo group, 12.2 recurrent VTEs occurred
per 100 patient-years with statin use compared with 13.2 per 100 patient-years without (adjusted HR 0.81; 95%
CI 0.35–1.86).
Conclusions: The effect of statins in this secondary analysis of the EINSTEIN VTE treatment program is consistent
with other studies that suggest a reduced risk of recurrent VTE, but conclusive evidence of this benefit is lacking.
Statins are simple to use, inexpensive, very safe and do not cause bleeding. Therefore, the potential effect on
reducing recurrent VTE, which is in the range of that of acetylsalicylic acid, deserves evaluation in a large
randomized trial.
Trial registration number: ClinicalTrials.gov: EINSTEIN PE, NCT00439777; EINSTEIN DVT, NCT00440193;
EINSTEIN Extension, NCT00439725.
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Statins are prescribed primarily with the aim of lowering
levels of low-density lipoprotein cholesterol in patients at
increased risk for cardiovascular events. In recent years,
there has been an interest in the potential of statins to
reduce the risk of venous thromboembolism (VTE), com-
prising deep vein thrombosis (DVT) and pulmonary em-
bolism (PE), driven by the publication of several studies
and meta-analyses suggesting a significant protective effect
[1-3]. However, the most recent meta-analysis showed an
odds ratio (OR) for a first venous thromboembolic event
for statin users of only 0.89 (95% confidence interval [CI]
0.78–1.01) compared with non-users [4]. Recently, registry
based studies suggested that statins could also diminish
the rate of recurrent VTE [5-7].
Anticoagulant therapy is the standard approach for the
treatment of VTE. In the large phase III EINSTEIN DVT
and PE program, the oral, direct Factor Xa inhibitor rivar-
oxaban was compared with parenteral enoxaparin and
oral vitamin K antagonist (VKA) for the acute treat-
ment of VTE [8-10], and with placebo for the extended
treatment of VTE [8]. A relatively high proportion of
patients enrolled in these studies were receiving concomi-
tant medication with statins. This post-hoc analysis evalu-
ated outcomes in terms of recurrent VTE and major




The methodology of the EINSTEIN DVT and PE program
has been described previously [8-10]. Briefly, more than
8000 patients with acute symptomatic, confirmed DVT
and/or symptomatic, confirmed and hemodynamically
stable PE were randomized to receive either fixed-dosed
rivaroxaban (15 mg twice-daily for 3 weeks followed by
20 mg once-daily) or standard treatment with enoxaparin
overlapping with and transitioning to VKA, adjusted to
maintain an international normalized ratio between 2.0
and 3.0. Treatment was continued for 3, 6 or 12 months.
For the extended treatment of VTE, more than 1100 patients
who had completed a 6–12 month course of anticoagulant
treatment were randomized to rivaroxaban 20 mg or pla-
cebo for an extra 6 or 12 month period [8].
Ethical approval was obtained from the Institutional
Review Boards of all institutions involved in the EIN-
STEIN studies, and written informed consent was pro-
vided by all patients [10].
The main exclusion criteria were another indication
for a VKA; a calculated creatinine clearance <30 ml/min
using the Cockcroft–Gault formula; clinically significant
liver disease or an alanine aminotransferase level that was
three times the upper limit of the normal range or higher;
active bleeding or a high risk of bleeding, contraindicatinganticoagulant treatment; systolic blood pressure greater
than 180 mm Hg or diastolic blood pressure greater
than 110 mm Hg; childbearing potential without proper
contraceptive measures, pregnancy, or breast-feeding;
concomitant use of strong cytochrome P450 3A4 inhibi-
tors (e.g. human immunodeficiency virus protease inhibi-
tors or systemic ketoconazole) or inducers (e.g. rifampicin,
carbamazepine or phenytoin); and a life expectancy of less
than 3 months. The protocols did not include guidelines
for the use of statins.
Patients were followed clinically and in case of a sus-
pected recurrent DVT/PE, a work-up using objective
diagnostic tests was required. Symptomatic recurrent
VTE was defined as a composite of fatal or non-fatal PE
or DVT on the basis of criteria that have been described
previously [8,9]. Death was classified as due to PE,
bleeding, or other established causes or diagnoses. PE
was considered the cause of death if there was objective
documentation of the condition or if death could not be
attributed to a documented cause and PE could not be
confidently ruled out. Bleeding was defined as major if it
was clinically overt and associated with a decrease in
hemoglobin of ≥2.0 g/dl; led to the transfusion of ≥2
units of red blood cells; was intracranial, retroperitoneal
or occurred in another critical site; or contributed to
death [8,9]. All suspected outcome events were classified
by a central adjudication committee whose members
were unaware of the treatment assignment.
Analysis
Concomitant medications taken during the studies were
collected at each visit on an electronic case record form,
and 100% source verification was done by a clinical re-
search associate. Statin therapies were coded according
to the WHO Drug Dictionary Version 2005/Q3 and
were defined via the Anatomical-Therapeutic-Chemical
(ATC) codes. Statins were classified as low, medium or
high potency based on their low-density lipoprotein re-
duction capacity, as previously described [7].
Analyses were performed in SAS version 9.2 (SAS In-
stitute Inc., Cary, NC, USA). The use of statin therapy
was categorized as either ‘on’ or ‘off ’ for each day be-
tween the day of randomization and the end of the pa-
tient’s at-risk period, which was defined as last intake of
rivaroxaban or enoxaparin/VKA (or placebo) plus 2 days,
or the onset date of 1) the first confirmed recurrent
DVT/PE, or 2) major bleeding, if these occurred earlier.
For the extended treatment study, major bleeding was
not analyzed, because only four major bleeding events
occurred [8]. Person-time was accumulated per patient
from the day of randomization until the end of the at-
risk period. Patients who were ‘on’ and ‘off ’ statin ther-
apy during the at-risk period contributed person-time
to both (‘on’ and ‘off ’) categories of exposure. The incidence
Table 1 Baseline characteristics of patients with and









Mean age, years 66.5 54.9 <0.01
Men, n (%) 847 (56.1) 3650 (54.2) 0.18




<50 ml/min 207 (13.7) 442 (6.6)
50–<80 ml/min 515 (34.1) 1500 (22.3)
≥80 ml/min 775 (51.4) 4736 (70.4)




3 months 75 (5.0) 580 (8.6)
6 months 858 (56.9) 4056 (60.3)
12 months 576 (38.2) 2095 (31.1)
Index event, n (%) <0.01
Only DVT 489 (32.4) 2880 (42.8)
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bleeding were expressed as incidence rates per 100 patient-
years of exposure (or not) to statins, both overall and by
age group (<60 years or ≥60 years) for statin users and
non-users in both treatment arms combined and separ-
ately. A Cox proportional hazards model was constructed,
stratified by index event and intended treatment duration,
with statin use as a time-dependent variable, for each
treatment group (rivaroxaban vs enoxaparin/VKA or pla-
cebo) and adjusted for acetylsalicylic acid (ASA) use, age
(<60 years vs ≥60 years), body mass index (≥30 kg/m2 vs
<30 kg/m2), cardiac disorders, sex, creatinine clearance at
baseline (≥50 ml/min vs <50 ml/min), and interaction be-
tween treatment group and statin use. P-values for
interaction were calculated. Separate models including
interaction between each covariate and statin use were
constructed to generate hazard ratios for use versus non-
use by category as well as p-values for interaction. Due to
zero cell counts, the Cox proportional hazards model for
the extended treatment study was only adjusted for age
and prior rivaroxaban or VKA treatment. A Poisson re-
gression was used to calculate the interaction p-value for












76 (5.0) 352 (5.2) 0.76
Ischemic heart
disease, n (%)
410 (27.2) 229 (3.4) <0.01
Peripheral arterial
disease, n (%)




53 (3.5) 45 (0.7) <0.01
ASA use at baseline,
n (%)
387 (26.5) 337 (5.0) <0.01Results
Patient demographics
Baseline demographic characteristics are summarized in
Table 1 for the acute EINSTEIN DVT and PE program
and in Table 2 for the extended rivaroxaban treatment
study. In total, 1509 (18.3%) patients included in the
acute EINSTEIN DVT or PE studies used statins (simva-
statin, n=716; atorvastatin, n=532; rosuvastatin, n=171;
others, n=164) and during the at-risk period, and 6731
(81.7%) did not. A total of 1223 (81.0%) patients used
statins throughout the-at-risk period. In the extended
treatment study, a total of 230 (19.4%) patients used sta-
tins during the at-risk period and 958 (80.6%) did not. In
all studies, statin users were older, presented more often
with PE, had higher frequencies of renal impairment and
cardiovascular disorders, and used ASA more often [11].ASA stopped at
randomization, n
85 122
Hypertension, n (%) 1052 (69.7) 2181 (32.4) <0.01
Diabetes, n (%) 392 (26.0) 512 (7.6) <0.01
ASA, acetylsalicylic acid; BMI, body mass index; DVT, deep vein thrombosis;
PE, pulmonary embolism; VKA, vitamin K antagonist.
Data from EINSTEIN DVT and EINSTEIN PE combined, safety population.Acute EINSTEIN DVT and PE studies
Recurrent venous thromboembolism
For the treatment groups combined, 20 recurrent VTEs
occurred during 783.8 patient-years (2.6 per 100 patient-
years) with statin use compared with 146 during 3872.1
patient-years (3.8 per 100 patient-years) without use of
statins, for an adjusted hazard ratio [HR] of 0.76 (95%
CI 0.46–1.25). Hazard ratios for recurrent VTE were simi-
lar for concomitant use of rivaroxaban-statin and enoxa-
parin/VKA-statin (pinteraction=0.47, Figure 1). Hazard
ratios for recurrent VTE with the use of statins were simi-
lar in all other important subgroups of patients (Figure 1).Recurrent VTE occurred in 1 (3.0%) per 100 patient-years
in the group of patients that used a low potency statin, in
14 (2.3%) per 100 patient-years in the group of patients
with a medium potency statin, and in 4 (4.1%) per
100 patient-years in the group of patients with a high
Table 2 Baseline characteristics with/without statin therapy for patients allocated to rivaroxaban and placebo
(shown separately)









Mean age, years 64.3 56.7 <0.01 66.9 56.3 <0.01
Men, n (%) 62 (54.9) 289 (59.6) 0.36 66 (56.4) 272 (57.5) 0.42
Mean BMI, kg/m2 29.9 28.1 <0.01 29.8 28.0 <0.01
Creatinine clearance, n (%) 0.20 <0.01
<50 ml/min 10 (8.8) 31 (6.4) 17 (14.5) 33 (7.0)
50–<80 ml/min 33 (29.2) 113 (23.3) 39 (33.3) 96 (20.3)
≥80 ml/min 68 (60.2) 335 (69.1) 60 (51.3) 340 (71.9)
Missing 2 (1.8) 6 (1.2) 1 (0.9) 4 (0.8)
Planned treatment duration, n (%) 0.14 0.19
6 months 61 (54.0) 298 (61.4) 68 (58.1) 285 (60.3)
12 months 52 (46.0) 187 (38.6) 49 (41.9) 188 (39.7)
Index event, n (%) <0.01 <0.01
Only DVT 48 (42.5) 325 (67.0) 54 (46.2) 292 (61.7)
PE ± DVT 61 (54.0) 151 (31.1) 61 (52.1) 172 (36.4)
Index event not confirmed 4 (3.5) 9 (1.9) 2 (1.7) 9 (1.9)
Immobilization at
randomization, n (%)
17 (15.0) 72 (14.8) 0.96 17 (14.5) 59 (12.5) 0.66
Active cancer at
randomization, n (%)
5 (4.4) 23 (4.7) 0.89 6 (5.1) 20 (4.2) 0.85
Ischemic heart disease, n (%) 19 (16.8) 14 (2.9) <0.01 40 (34.2) 20 (4.2) <0.01
Peripheral arterial disease, n (%) 1 (0.9) 2 (0.4) 1 (0.9) 0
Ischemic cerebrovascular
disease, n (%)
0 4 (0.8) 2 (1.7) 5 (1.1)
ASA use at baseline, n (%) 5 (4.4) 15 (3.1) <0.01 29 (24.8) 18 (3.8) <0.01
ASA stopped at randomization, n 0 3 0 0
Hypertension, n (%) 80 (70.8) 161 (33.2) <0.01 73 (62.4) 154 (32.6) <0.01
Diabetes, n (%) 30 (26.5) 28 (5.8) <0.01 35 (29.9) 21 (4.4) <0.01
ASA, acetylsalicylic acid; BMI, body mass index; DVT, deep vein thrombosis; PE, pulmonary embolism.
Data from EINSTEIN Extension, safety population.
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oxaban and enoxaparin/VKA patients (pinteraction=0.84).
Major bleeding
For the treatment groups combined, 23 major bleeding
events occurred during 778.8 patient-years (3.0 per
100 patient-years) with statin use compared with 89
during 3884.2 patient-years (2.3 per 100 patient-years)
without use of statins, for an adjusted HR of 0.77 (95% CI
0.46–1.29). Due to the adjustments in the Cox regression
model, the direction of this HR is in contrast to the crude
comparison of rates by patient-years. This is largely be-
cause, in general, statin users are older and most of the
major bleeding events in statin users occurred in the
≥60 years age group. Hazard ratios for major bleeding
were similar for concomitant use of rivaroxaban-statinand enoxaparin/VKA-statin (pinteraction=0.77, Figure 2).
Hazard ratios for major bleeding with the use of statin




In the rivaroxaban group, no recurrent VTE occurred dur-
ing 66.2 patient-years (0 per 100 patient-years) with statin
use compared with 4 during 249.7 patient-years (1.6 per
100 patient-years) without use of statins (no HR calculated
due to zero events). In the placebo group, 7 recurrent VTEs
occurred during 57.3 patient-years (12.2 per 100 patient-years)
with statin use compared with 33 during 249.9 patient-years
(13.2 per 100 patient-years) without use of statins, for
an adjusted HR of 0.81 (95% CI 0.35–1.86).
Figure 1 Hazard ratio and 95% CIs for recurrent VTE by statin use versus no statin use. Important subgroups of patients in the EINSTEIN DVT
and PE studies. ASA, acetylsalicylic acid; BMI, body mass index; CI, confidence interval; CrCl, creatinine clearance; HR, hazard ratio; VKA, vitamin K
antagonist; VTE, venous thromboembolism.
Figure 2 Hazard ratio and 95% CIs for major bleeding by statin use versus no statin use. Important subgroups of patients in the EINSTEIN DVT
and PE studies. ASA, acetylsalicylic acid; BMI, body mass index; CI, confidence interval; CrCl, creatinine clearance; HR, hazard ratio; VKA, vitamin K
antagonist; VTE, venous thromboembolism.
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A total of 40 cardiovascular ischemic events occurred in
the statin users group, of which 15 occurred in the rivar-
oxaban group and 25 in the comparator group.
Discussion
This secondary analysis of the EINSTEIN VTE treat-
ment program showed that the use of concomitant sta-
tin therapy resulted in a moderate but non-statistically
significant reduction in the rate of recurrent VTE in pa-
tients receiving anticoagulants or placebo. Major bleed-
ing was numerically more common in patients receiving
statin therapy but the adjusted hazard ratio showed a
modest non-significant reduction; a phenomenon largely
caused by a substantial age difference between statin
users and non-users.
Interest in the possible pleiotropic effects of statins on
VTE is not new [11,12]. In the early 2000s, retrospective
cohort and case control studies investigating the potential
of statins to prevent VTE appeared in the literature
[11,13,14]. The first randomized trial showed a 50% reduc-
tion in VTE risk in statin users versus non-users [15].
Subsequently, in the large randomized JUPITER trial in
apparently healthy subjects at low risk of cardiovascular
disease, rosuvastatin reduced the risk of VTE by more
than 40% versus placebo [16]. However, a meta-analysis of
22 randomized trials with over 100,000 patients, compar-
ing statins versus control in primary VTE prevention, sug-
gested only a modest overall treatment effect with any
statin (OR 0.89; 95% CI 0.78–1.01), although a subgroup
analysis by statin suggested that rosuvastatin may be the
most effective statin (OR 0.60; 95% CI 0.39–0.92) [4].
Evaluation of statins for secondary VTE prevention has
only been done in observational studies and has shown
similar results to our study. In two Danish population-
based registries among patients with a hospital diagnosis
of VTE, statin use was associated with a significantly
lower risk of a recurrent VTE (adjusted HR 0.74; 95% CI
0.68–0.80 and 0.72; 95% CI 0.59–0.88, respectively) for re-
current VTE, compared with no statin use [5]. In a recent
Dutch population-based registry of pharmacy records
linked with hospital discharge records of patients hospital-
ized with an acute episode of PE, concomitant treatment
with statins was associated with a reduced risk of re-
current PE (HR 0.50; 95% CI 0.36–0.70) [7]. This effect
was observed both during and after stopping anti-
coagulant therapy. In addition, a dose–response rela-
tionship was shown for potency of statin therapy. The
registries are limited by their retrospective assembly of
cases and controls and the absence of standardized
outcome assessments.
Some methodological aspects of our analysis warrant
comment. First, the analyses of efficacy and safety with
the use of statins were not pre-specified in the protocolor statistical analysis plan and there was no guidance in
the protocol on the use of statins. Second, there were
large differences in age, presentation of index event, co-
morbidity and ASA use between the patients who used
and did not use statins. Hence, all calculations of the
relative effects of statins were adjusted for these im-
portant variables. Nevertheless, residual confounding is
possible because it cannot be guaranteed that all under-
lying confounding factors could be considered in the
models. We believe that the differences in age, co-
morbidity and ASA use are based on the indication for
statin use. More surprisingly was the difference in the
distribution of the presentation of index event with an
excess of PE in statin users. An explanation for this dif-
ference could be that patients who use statins are more
likely to be evaluated for PE when they present to an
emergency room with shortness of breath or thoracic
pain. An alternative explanation could be based on the
well described anti-inflammatory properties of statins
[17-21], which may limit pain and other inflammatory
symptoms that usually lead to a suspicion of DVT and
presentation to the emergency room. Third, the literature
supports a potentially higher risk of venous thrombo-
embolic disease in patients with concomitant atheroscler-
otic disease [22-24]. Therefore, the observed hazard ratio
could be an underestimation although we adjusted for
cardiovascular co-morbidity. Finally, the power of the
current analyses, including the dose–response analysis,
was limited because only 1509 (18.3%) patients used
statins. Actually, to detect a reduction in recurrent
VTE of 24%, the overall effect observed in our analysis,
a suitably powered 1:1 randomized study should include
over 17,000 patients per group.
Our analyses have the following strengths: the use
of statin medication was prospectively collected, in-
tensively monitored, and centrally coded. Recurrent
VTE and bleeding events were prospectively collected
as well, and were reported using standardized forms.
In addition, these events were adjudicated centrally
using internationally accepted criteria without know-
ledge of treatment assignment and use of concomitant
medication.Conclusions
Statins are simple to use, inexpensive, very safe and do
not lead to bleeding. Therefore, the potential effect on
recurrent VTE, which is in the range of that of ASA,
deserves evaluation in a large randomized trial.Abbreviations
ASA: Acetylsalicylic acid; CI: Confidence interval; DVT: Deep vein thrombosis;
HR: Hazard ratio; OR: Odds ratio; PE: Pulmonary embolism; VKA: Vitamin K
antagonist; VTE: Venous thromboembolism.
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